On Wednesday, September 25, the UK’s Competition and Markets Authority (CMA) opened the public comment period for its antitrust investigation of the acquisition of Spark Therapeutics by Roche Holdings.
The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
